Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes

Annals of Hematology

Volumn 84, Issue 6, 2005, Pages 383-388

  Yamaguchi, Noritaka ^a   Ito, Yoshikazu ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Collagenase; Infection prognostic factor; Matrix metalloproteinases; Myelodysplastic syndromes

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HEALING; HUMAN; HUMAN CELL; INFECTION; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS;

ABSCESS; ADULT; CELLULITIS; CONVALESCENCE; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INFECTION; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; PNEUMONIA; PROGNOSIS; SEPSIS;

EID: 20444474203     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0965-5     Document Type: Article

References (29)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336 10.1016/0092-8674(91)90642-C
2. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135-1149 1:CAS:528:DC%2BD3cXitVCgsbg%3D
3. Alexander JS, Elrod JW (2002) Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 200:561-574 10.1046/j.1469-7580.2002.00057.x
4. Armstrong DG, Jude EB (2002) The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 92:12-18 11796794
5. Martin EL, Moyer BZ, Pape MC, Starcher B, Leco KJ, Veldhuizen RA (2003) Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis. Am J Physiol Lung Cell Mol Physiol 285:L1222-L1232 1:CAS:528:DC%2BD2cXhtlOh
6. Dubois B, Starckx S, Pagenstecher A, Oord J, Arnold B, Opdenakker G (2002) Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 32:2163-2171
7. Bottcher T, Spreer A, Azeh I, Nau R, Gerber J (2003) Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett 338:201-204
8. Yamada K, Yoshino K, Sekikawa K, Madarame H, Yagita H, Nakane A (2000) Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection. FEMS Immunol Med Microbiol 29:187-194 10.1016/S0928-8244(00)00204-2
9. Lalu MM, Gao CQ, Schulz R (2003) Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: A potential role for MMP-9. Mol Cell Biochem 251:61-66 10.1023/A:1025417529167
10. Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H (1998) Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 316:355-360 10.1097/ 00000441-199812000-00001
11. Itoh Y, Kuratsuji K, Aizawa S, Sai M, Ohyashiki K, Toyama K (1991) Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. Ann Hematol 63:270-275 1:STN:280:By2D28bhsVQ%3D
12. Ito Y, Ponnappan U, Lipschitz DA (1996) Excess formation of lysophosphatidic acid with age inhibits myristic acid-induced superoxide anion generation in intact human neutrophils. FEBS Lett 394:149-152 10.1016/0014-5793(96)00937-4
13. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD (1998) Double esterase staining and other neutrophilic granule abnormalities in 237 patients with the myelodysplastic syndrome studied by the cancer and leukemia group B. Acta Haematol 100:13-16 10.1159/000040855
14. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD (1997) Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: A common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res 21:801-806 10.1016/S0145-2126(97)00053-2
15. Moretti S, Lanza F, Spisani S, Latorraca A, Rigolin GM, Giuliani AL, Castoldi GL, Traniello S (1994) Neutrophils from patients with myelodysplastic syndromes: Relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma 13:471-477 1:STN:280:ByuA2cfjvVI%3D
16. Ito Y, Kawanishi Y, Shoji N, Ohyashiki K (2000) Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infection in patients with myelodysplastic syndrome. Clin Infect Dis 31:1292-1295 10.1086/317470
17. Mollinedo F, Nakajima M, Llorens A, Barbosa E, Callejo S, Gajate C, Fabra A (1998) Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils. Biochem J 327:917-923
18. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532-1535 10.1126/science.1092385
19. Hakoda Y, Ito Y, Nagate A, Minemura K, Utsumi K, Aoshima M, Ohyashiki K (2003) Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer. Thorax 58:122-126 10.1136/thorax.58.2.122
20. Rothe G, Klingel S, Assfalg-Machleidt I, Machleidt W, Zirkelbach C, Banati RB, Mangel WF, Valet G (1992) Flow cytometric analysis of protease activities in vital cells. Biol Chem Hoppe Seyler 373:547-554 1:CAS:528:DyaK3sXislaq
21. Ito Y, Lipschitz DA (2002) Assay of intracellular hydrogen peroxide generation in activated individual neutrophils by flow cytometry. Methods Mol Biol 196:111-116 1:CAS:528:DC%2BD38XlvVKqsL0%3D
22. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 1:STN:280:ByiB3M7ns1c%3D
23. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W (1994) Risk assessment in primary myelodysplastic syndromes: Validation of the Düsseldorf score. Leukemia 8:1906-1913 1:STN:280:ByqD2MjjtVU%3D
24. Yang R, Han ZC (2002) Angiogenesis in hematologic malignancies and its clinical implications. Int J Hematol 75:246-256 11999351
25. Mufti G, List AF, Gore SD, Ho AY (2003) Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 176-199
26. Musto P (2004) Thalidomide therapy for myelodysplastic syndrome: Current status and future perspectives. Leuk Res 28:325-332 10.1016/ j.leukres.2003.08.007
27. Arimura K, Arima N, Matsushita K, Ohtsubo H, Fujisawa H, Kukita T, Ozaki A, Hagiwara T, Hamada H, Yoshino K, Tei C (2004) Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 73:17-24 10.1111/j.1600-0609.2004.00261.x
28. Albert J, Radomski A, Soop A, Sollevi A, Frostell C, Radomski MW (2003) Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 47:407-410 1:CAS:528:DC%2BD3sXjs1ahs7c%3D
29. C Aul A Giagounidis U Germing 2002 Application of single and multiple prognostic factors in the assessment of patients with the myelodysplastic syndromes In: JM Bennett (Ed.) The myelodysplastic syndromes: Pathobiology and clinical management Marcel Dekker New York 203-249